Introduction:
Miltefosine is an oral medication used to treat leishmaniasis. Miltefosine can cause mild to moderate liver enzyme increases during the first two weeks of treatment. However, it is not linked to liver damage with jaundice.
Background:
Miltefosine is an alkylated phosphocholine that has been demonstrated to be effective against a range of microbial pathogens, including several species of Leishmania. The mechanism of action of miltefosine involves disruption of the microbial cell membranes and mitochondria. Miltefosine has been demonstrated to be an effective treatment for visceral, mucosal, and cutaneous leishmaniasis. Miltefosine received regulatory approval in India in 2002 and in the United States in 2014. It was the inaugural oral treatment for visceral and cutaneous leishmaniasis. The drug is available in 50 mg capsules under the brand name Impavido. The dosage is 50 mg twice a day for patients with a body weight of 30 to 44 kg, and three times a day for patients with a body weight of 45 kg or above. The treatment should be continued for 28 days. Additionally, miltefosine has been documented to demonstrate efficacy in the treatment of other serious bacterial, fungal, and parasitic conditions. Nevertheless, it has not been formally approved for these indications. Miltefosine is generally well tolerated, although adverse effects may occur, including nausea, vomiting, diarrhea, abdominal discomfort, anorexia, headache, dizziness, and drowsiness. Rare but severe adverse effects include infertility, fetal toxicity, renal dysfunction, and anaphylactic reactions. Miltefosine is seldom utilized in the United States, yet it is a crucial global medication. It has been instrumental in public health initiatives to eradicate visceral and cutaneous leishmaniasis.
Use:
Miltefosine is employed in the treatment of specific forms of leishmaniasis, including visceral leishmaniasis (which affects internal organs), cutaneous leishmaniasis (which affects the skin), and mucosal leishmaniasis (which affects the nose, mouth, or throat).
Direction:
Miltefosine is the only recognized oral agent with the potential to treat leishmaniasis. Previous studies have demonstrated that miltefosine has very good cure rates for visceral leishmaniasis (VL) in India, Nepal, and Bangladesh. However, recent reports have indicated that high rates of clinical failures have been observed.